121 related articles for article (PubMed ID: 11249123)
1. Non-peptidic inhibitors of human chymase. Synthesis, structure-activity relationships, and pharmacokinetic profiles of a series of 5-amino-6-oxo-1,6-dihydropyrimidine-containing trifluoromethyl ketones.
Akahoshi F; Ashimori A; Yoshimura T; Imada T; Nakajima M; Mitsutomi N; Kuwahara S; Ohtsuka T; Fukaya C; Miyazaki M; Nakamura N
Bioorg Med Chem; 2001 Feb; 9(2):301-15. PubMed ID: 11249123
[TBL] [Abstract][Full Text] [Related]
2. Nonpeptidic chymase inhibitors: design and structure-activity relationships of pyrimidinone derivatives based on the predicted binding mode of a peptidic inhibitor.
Akahoshi F
Curr Pharm Des; 2003; 9(15):1191-9. PubMed ID: 12769746
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, structure-activity relationships, and pharmacokinetic profiles of nonpeptidic difluoromethylene ketones as novel inhibitors of human chymase.
Akahoshi F; Ashimori A; Sakashita H; Yoshimura T; Eda M; Imada T; Nakajima M; Mitsutomi N; Kuwahara S; Ohtsuka T; Fukaya C; Miyazaki M; Nakamura N
J Med Chem; 2001 Apr; 44(8):1297-304. PubMed ID: 11312928
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, structure-activity relationships, and pharmacokinetic profiles of nonpeptidic alpha-keto heterocycles as novel inhibitors of human chymase.
Akahoshi F; Ashimori A; Sakashita H; Yoshimura T; Imada T; Nakajima M; Mitsutomi N; Kuwahara S; Ohtsuka T; Fukaya C; Miyazaki M; Nakamura N
J Med Chem; 2001 Apr; 44(8):1286-96. PubMed ID: 11312927
[TBL] [Abstract][Full Text] [Related]
5. Peptidyl human heart chymase inhibitors. 2. Discovery of highly selective difluoromethylene ketone derivatives with Glu at P3 site.
Eda M; Ashimori A; Akahoshi F; Yoshimura T; Inoue Y; Fukaya C; Nakajima M; Fukuyama H; Imada T; Takai S; Shiota N; Miyazaki M; Nakamura N
Bioorg Med Chem Lett; 1998 Apr; 8(8):919-24. PubMed ID: 9871512
[TBL] [Abstract][Full Text] [Related]
6. Peptidyl human heart chymase inhibitors. 1. Synthesis and inhibitory activity of difluoromethylene ketone derivatives bearing P' binding subsites.
Eda M; Ashimori A; Akahoshi F; Yoshimura T; Inoue Y; Fukaya C; Nakajima M; Fukuyama H; Imada T; Takai S; Shiota N; Miyazaki M; Nakamura N
Bioorg Med Chem Lett; 1998 Apr; 8(8):913-8. PubMed ID: 9871511
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and structure-activity relationships of a new class of 1-oxacephem-based human chymase inhibitors.
Aoyama Y; Uenaka M; Konoike T; Iso Y; Nishitani Y; Kanda A; Naya N; Nakajima M
Bioorg Med Chem Lett; 2000 Nov; 10(21):2397-401. PubMed ID: 11078187
[TBL] [Abstract][Full Text] [Related]
8. Development of the chymase inhibitor as an anti-tissue-remodeling drug: myocardial infarction and some other possibilities.
Sukenaga Y; Kamoshita K; Takai S; Miyazaki M
Jpn J Pharmacol; 2002 Nov; 90(3):218-22. PubMed ID: 12499575
[TBL] [Abstract][Full Text] [Related]
9. 1-Oxacephem-based human chymase inhibitors: discovery of stable inhibitors in human plasma.
Aoyama Y; Uenaka M; Konoike T; Iso Y; Nishitani Y; Kanda A; Naya N; Nakajima M
Bioorg Med Chem Lett; 2000 Nov; 10(21):2403-6. PubMed ID: 11078188
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity relationship studies of chloromethyl ketone derivatives for selective human chymase inhibitors.
Hayashi Y; Iijima K; Katada J; Kiso Y
Bioorg Med Chem Lett; 2000 Feb; 10(3):199-201. PubMed ID: 10698435
[TBL] [Abstract][Full Text] [Related]
11. Substituted 3-(phenylsulfonyl)-1-phenylimidazolidine-2,4-dione derivatives as novel nonpeptide inhibitors of human heart chymase.
Niwata S; Fukami H; Sumida M; Ito A; Kakutani S; Saitoh M; Suzuki K; Imoto M; Shibata H; Imajo S; Kiso Y; Tanaka T; Nakazato H; Ishihara T; Takai S; Yamamoto D; Shiota N; Miyazaki M; Okunishi H; Kinoshita A; Urata H; Arakawa K
J Med Chem; 1997 Jul; 40(14):2156-63. PubMed ID: 9216834
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and pharmacological evaluation of 3-benzylazetidine-2-one-based human chymase inhibitors.
Aoyama Y; Uenaka M; Kii M; Tanaka M; Konoike T; Hayasaki-Kajiwara Y; Naya N; Nakajima M
Bioorg Med Chem; 2001 Nov; 9(11):3065-75. PubMed ID: 11597491
[TBL] [Abstract][Full Text] [Related]
13. Structure-based design, synthesis, and binding mode analysis of novel and potent chymase inhibitors.
Futamura-Takahashi J; Tanaka T; Sugawara H; Iwashita S; Imajo S; Oyama Y; Muto T
Bioorg Med Chem Lett; 2018 Jan; 28(2):188-192. PubMed ID: 29191554
[TBL] [Abstract][Full Text] [Related]
14. Vascular chymase: pathophysiological role and therapeutic potential of inhibition.
Doggrell SA; Wanstall JC
Cardiovasc Res; 2004 Mar; 61(4):653-62. PubMed ID: 14985062
[TBL] [Abstract][Full Text] [Related]
15. 1,2-Benzisothiazol-3-one 1,1-dioxide inhibitors of human mast cell tryptase.
Combrink KD; Gülgeze HB; Meanwell NA; Pearce BC; Zulan P; Bisacchi GS; Roberts DG; Stanley P; Seiler SM
J Med Chem; 1998 Nov; 41(24):4854-60. PubMed ID: 9822554
[TBL] [Abstract][Full Text] [Related]
16. The 2.2 A crystal structure of human chymase in complex with succinyl-Ala-Ala-Pro-Phe-chloromethylketone: structural explanation for its dipeptidyl carboxypeptidase specificity.
Pereira PJ; Wang ZM; Rubin H; Huber R; Bode W; Schechter NM; Strobl S
J Mol Biol; 1999 Feb; 286(1):163-73. PubMed ID: 9931257
[TBL] [Abstract][Full Text] [Related]
17. Peptide boronic acids, substrate analogs, inhibit chymase, and histamine release from rat mast cells.
Kato Y; Kido H; Fukusen N; Katunuma N
J Biochem; 1988 May; 103(5):820-2. PubMed ID: 2460436
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors of chymase as mast cell-stabilizing agents: contribution of chymase in the activation of human mast cells.
He S; Gaça MD; McEuen AR; Walls AF
J Pharmacol Exp Ther; 1999 Nov; 291(2):517-23. PubMed ID: 10525066
[TBL] [Abstract][Full Text] [Related]
19. Mammalian chymotrypsin-like enzymes. Comparative reactivities of rat mast cell proteases, human and dog skin chymases, and human cathepsin G with peptide 4-nitroanilide substrates and with peptide chloromethyl ketone and sulfonyl fluoride inhibitors.
Powers JC; Tanaka T; Harper JW; Minematsu Y; Barker L; Lincoln D; Crumley KV; Fraki JE; Schechter NM; Lazarus GG
Biochemistry; 1985 Apr; 24(8):2048-58. PubMed ID: 3893542
[TBL] [Abstract][Full Text] [Related]
20. Chymase: its pathophysiological roles and inhibitors.
Fukami H; Okunishi H; Miyazaki M
Curr Pharm Des; 1998 Dec; 4(6):439-53. PubMed ID: 10197055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
